key: cord-1011372-lt3lg7h8
authors: Zhang, Litao
title: Response to “uncertainties on the prognostic value of D‐dimers in COVID‐19 patients”
date: 2020-05-14
journal: J Thromb Haemost
DOI: 10.1111/jth.14899
sha: e9026277a49ca5c99f7a32f0873a467eda233a34
doc_id: 1011372
cord_uid: lt3lg7h8

We appreciate the opportunity to respond to the letter from Dr Gris and colleagues. It is true there were several limitations in our study. However, we still believe that D‐dimer level at admission could be an effective and easily available predictor in patients with coronavirus disease 2019 (COVID‐19).

We appreciate the opportunity to respond to the letter from Dr Gris and colleagues. It is true there were several limitations in our study. However, we still believe that D-dimer level at admission could be an effective and easily available predictor in patients with coronavirus disease 2019 (COVID-19).

First, selection bias was the first limitation we have mentioned in discussion section [1] .

Selection bias was mainly attributed to single-center, the native of retrospective study, and the limit condition during early outbreak of COVID-19 in Wuhan, China. A total of 712 patients with COVID-19 were admitted to our hospital during the outbreak, we had enrolled all 343 eligible patients who had D-dimer levels and definite outcomes (dead or survival). Generally, D-dimer, as one of coagulation profile, should be ordered on admission for every patient with COVID-19.

Because our clinicians had realized that D-dimer could be a good marker in management of COVID-19 patients, which was supported by Wang and colleagues at the early outbreak [2] .

However, due to limit number of medical staffs, many patients had not been performed D-dimer tests on admission, especially those mild cases.

Second, a well-designed prospective cohort study could provide higher-level evidence to confirm the prognosis value of D-dimer in patients with COVID-19. However, the number of new diagnosed COVID-19 is too rare to conduct a prospective study in China now. So, a standardized, pooled, multi-center retrospective study might have more operability, which is also our expectation.

Third, we did not think anticoagulation or antithrombotic before admission would have observably impact on predictive value of D-dimer in COVID-19 patients. Because oral anticoagulation before admission was a stable progress producing stable D-dimer level.

Furthermore, in a previous review, elevated D-dimer can also be well-used to predict unfavorable outcomes in patients during oral anticoagulation [3] .

The main purpose of our study was to provide a simple and easy use marker to distinguish those who might with high mortality risks on admission. Anticoagulation therapy in hospital might decrease D-dimer level, but actually it is just one of clinical interventions, there were also many other similar factors might impact predictive value of D-dimer, such as hormonotherapy, antibiotic

This article is protected by copyright. All rights reserved therapy et al. Furthermore, the number of events was too small to perform full-adjusted analysis, which we also mentioned in our study [1] . Thus, the impact of clinical intervention, including but not limited to anticoagulation on predictive value of D-dimer should be assessed by future studies with bigger sample sizes.

Forth, due to a 7-8 hours of half-life in-vivo, D-dimer is quite suitable to be a dynamic monitor of COVID-19 progression. Two retrospective studies had reported that D-dimer showed markedly and continuously rising in those non-survivors [2, 4] . However, we don't think that the area under the D-dimer level curve obtained day after day could be a good prognostic marker, due to that the water-line of D-dimer differed greatly among patients, it is too difficult to ensure D-dimer testing would be performed day after day in every patient, and it is not friendly to use for clinicians.

Fifth, As shown in Figure 2 in our study [1] , Statistical significance of separation between patients with D-dimer ≥2.0 μg/ml and those with D-dimer <2.0 μg/ml was achieved at seven days after admission. Dynamic monitor might provide more information to predict death. It can be said that the higher D-dimer level was, the higher the mortality risk was.

Sixth, we did not provide multivariate analysis of confounders. Instead, we performed a Cox proportional hazard analysis with adjustment of age, gender and underlying diseases in our study to evaluate the independent predictive value of D-dimer. Given the limited number of events, there might be no enough reliability of perform multivariate analysis. Furthermore, the pure multivariate analysis might add nothing in management of COVID-19 patients. The optimum approach to use these confounders may be to establish a multiple-parameter prediction model. D-dimer, as one of key markers of severe coagulopathy, which has been observed to be common in non-survivors of COVID-19. Up to now, the use of D-dimer in management of COVID-19 is attracting more and more attention. We are expecting further studies to describe more details.

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020

Use of D-dimer in oral anticoagulation therapy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study